Literature DB >> 12797313

Evidence of human immunodeficiency virus-associated lipodystrophy syndrome in children treated with protease inhibitors.

James L Bockhorst1, Iyad Ksseiry, Maripat Toye, Stuart R Chipkin, Barbara W Stechenberg, Donna J Fisher, Holley F Allen.   

Abstract

We conducted a prospective evaluation for evidence of the HIV-associated lipodystrophy syndrome of 26 children infected with HIV-1. Six children had evidence of body fat redistribution. Nine children showed laboratory evidence of insulin resistance. All children with body fat distribution or insulin resistance had been treated with protease inhibitors. Children treated with protease inhibitors had higher total cholesterol, higher low density lipoprotein-cholesterol and higher triglycerides than untreated children.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12797313

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  16 in total

1.  Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study.

Authors:  Denise L Jacobson; Kunjal Patel; George K Siberry; Russell B Van Dyke; Linda A DiMeglio; Mitchell E Geffner; Janet S Chen; Elizabeth J McFarland; William Borkowsky; Margarita Silio; Roger A Fielding; Suzanne Siminski; Tracie L Miller
Journal:  Am J Clin Nutr       Date:  2011-11-02       Impact factor: 7.045

2.  Prevalence of lipodystrophy in HIV-infected children: a cross-sectional study.

Authors:  Luminita Ene; Tessa Goetghebuer; Marc Hainaut; Alexandra Peltier; Véronique Toppet; Jack Levy
Journal:  Eur J Pediatr       Date:  2006-07-29       Impact factor: 3.183

Review 3.  Impact of antiretroviral therapy on growth, body composition and metabolism in pediatric HIV patients.

Authors:  Roy J Kim; Richard M Rutstein
Journal:  Paediatr Drugs       Date:  2010-06       Impact factor: 3.022

4.  Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children.

Authors:  Ana María Sánchez Torres; Raquel Munoz Muniz; Rosario Madero; Clementina Borque; María Jesús García-Miguel; María Isabel De José Gómez
Journal:  Eur J Pediatr       Date:  2005-01-14       Impact factor: 3.183

5.  Lipodystrophy and metabolic complications of highly active antiretroviral therapy.

Authors:  Ankit Parakh; Anand Prakash Dubey; Ajay Kumar; Anshu Maheshwari
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

6.  Is resistin a link between highly active antiretroviral therapy and fat redistribution in HIV-infected children?

Authors:  M I Spagnuolo; E Bruzzese; G F Vallone; N Fasano; G De Marco; A Officioso; G Valerio; M Volpicelli; R Iorio; A Franzese; A Guarino
Journal:  J Endocrinol Invest       Date:  2008-07       Impact factor: 4.256

7.  Short communication: High prevalence of vitamin D deficiency in HIV-infected and HIV-uninfected pregnant women.

Authors:  Allison Ross Eckard; Traci Leong; Ann Avery; Marina Duran Castillo; Hector Bonilla; Norma Storer; Danielle Labbato; Alka Khaitan; Vin Tangpricha; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2013-06-15       Impact factor: 2.205

Review 8.  Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.

Authors:  Ovidiu Galescu; Amrit Bhangoo; Svetlana Ten
Journal:  Rev Endocr Metab Disord       Date:  2013-06       Impact factor: 6.514

9.  The relationship between vitamin D status and HIV-related complications in HIV-infected children and young adults.

Authors:  Allison Ross Eckard; Vin Tangpricha; Shabnam Seydafkan; Mary Ann O'Riordan; Norma Storer; Danielle Labbato; Grace A McComsey
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

10.  Longitudinal changes in regional fat content in HIV-infected children and adolescents.

Authors:  Stephen M Arpadi; James Bethel; Mary Horlick; Moussa Sarr; Marukh Bamji; Elaine J Abrams; Murli Purswani; Ellen S Engelson
Journal:  AIDS       Date:  2009-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.